Hikma wins US FDA approval for generic Vascepa for the heart
22 May 2020 -

Generic pharmaceutical company Hikma Pharmaceuticals plc (LSE:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY) reported on Thursday that its wholly owned US subsidiary Hikma Pharmaceuticals USA Inc has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm.

The drug is indicated to reduce the risk of heart attack, stroke and other types of heart problems.

Icosapent Ethyl Capsules are the generic equivalent to Vascepa, which is a registered trademark of Amarin Pharmaceuticals Ireland Limited.

In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa patents owned by Amarin. The District Court decision is currently being appealed.